WHAT WE DO
We use our integrative research process to uncover and leverage the best opportunities in emerging high-growth tech-driven segments for the benefit of the investors and growth companies we serve, as well as our broader society and environment. Integrative research draws heavily on our relationships with companies and unifies naturally divergent perspectives, capabilities, skill sets, and relationships, yielding a deep, comprehensive understanding of each segment's near-term and long-term potential.
|
Technology / SaaS
|
Healthcare
|
Environmental Technology
VENTURE
CAPITAL
CAPITAL
First Analysis is a leading venture capital investor, having invested more than $825 million over four decades. Leveraging our integrative research process, we partner with strong teams leading rapid-growth companies to build industry leaders in the targeted sectors where we are acknowledged experts and where success benefits not only our investors, but also our broader society and environment.
INTEGRATIVE
RESEARCH
RESEARCH
Integrative research means our extensive company research informs every thesis and perspective. The result is deep industry knowledge, expertise, and trend insights that yield valuable results for our clients and partners.
INVESTMENT
BANKING
BANKING
Our investment bankers have a wealth of industry knowledge, contacts, and execution expertise to drive strategic transactions with uncompromised loyalty to our clients.
NEWS & INSIGHTS
|
First Analysis invests in Applied StemCell, a leading cell and gene therapy CRO/CDMO
First Analysis, a leading venture capital investor, has made a new investment in Applied StemCell (ASC), a contract development and manufacturing organization (CDMO) specializing in tailored cell and gene therapy solutions. First Analysis co-invested in ASC alongside QHP Capital.
July 16, 2024
First Analysis, a leading venture capital investor, has made a new investment in Applied StemCell (ASC), a contract development and manufacturing organization (CDMO) specializing in tailored cell and gene therapy solutions. First Analysis co-invested in ASC alongside QHP Capital.
July 16, 2024
|
First Analysis invests in Sware, provider of FDA-mandated computer system validation automation for GxP systems and release testing
First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and development of Sware's computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company's sales team so it can bring the platform to more organizations struggling with validation debt.
June 07, 2024
First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and development of Sware's computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company's sales team so it can bring the platform to more organizations struggling with validation debt.
June 07, 2024
|
First Analysis acted as the exclusive financial advisor to Pharmacy Quality Solutions in its sale to Innovaccer
First Analysis acted as the exclusive financial advisor to Pharmacy Quality Solutions (PQS), a leading pharmacy-payer performance technology, in its sale to Innovaccer. The terms of the transaction were not disclosed.
March 22, 2024
First Analysis acted as the exclusive financial advisor to Pharmacy Quality Solutions (PQS), a leading pharmacy-payer performance technology, in its sale to Innovaccer. The terms of the transaction were not disclosed.
March 22, 2024